Parsaclisib & Sirolimus Gel Filed In EU For Rare Diseases
Executive Summary
Incyte’s next-generation PI3K-delta inhibitor, parsaclisib, and Nobelpharma’s topical sirolimus gel are among the latest marketing authorization applications that have been filed in the EU.
You may also be interested in...
New EU Filings
Natalizumab, Polpharma Biologics’ proposed biosimilar to Biogen’s Tysabri for treating relapsing-remitting multiple sclerosis, is among the latest medicines that have been submitted for review for potential pan-EU approval.
New EU Filings
Adagrasib, Mirati Therapeutics' treatment for patients with non-small cell lung cancer, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
New EU Filings
Tislelizumab, Novartis/BeiGene’s drug for treating esophageal and non-small cell lung cancer, is among the latest new medicines that have been submitted for review for potential pan-EU approval.